Top CCI Findings—and How to Prevent Them


Published on 02/12/2025

Top CCI Findings—and How to Prevent Them

Understanding Extractables and Leachables in Pharmaceutical Packaging

The pharmaceutical industry is heavily regulated, emphasizing the safety, efficacy, and quality of drug products. One of the critical aspects of ensuring these attributes is through the qualification of packaging systems, specifically focusing on extractables and leachables (E&L). E&L can significantly impact the stability and safety of pharmaceuticals, particularly those in liquid form. It is essential to identify these materials early in the development process to prevent detrimental effects on product quality.

Extractables refer to substances that can be extracted from a material under aggressive conditions, while leachables are those that can migrate from the packaging into the drug product under normal storage conditions. The FDA provides clear guidelines on the testing required for packaging systems, including methods to assess E&L to ensure compliance with cGMP practices.

In this tutorial, we will walk through various steps to identify, assess, and mitigate risks associated with E&L findings, particularly focusing on container closure integrity (CCI) and the principles outlined in the USP guidelines.

Step 1: Implementing a Comprehensive E&L Risk Assessment

Before delving into practical testing, it is vital to start with a comprehensive E&L risk assessment. This assessment allows pharmaceutical manufacturers to understand the potential risks associated with specific packaging materials and their compatibility with drug formulations.

  • Identify Materials: Catalog all materials used in container/closure systems including polymers, adhesives, and seals.
  • Characterize Materials: Evaluate their chemical compositions, structures, and potential contaminants using analytical methods.
  • Define Extraction Conditions: Establish extraction methodologies that will mimic both real-world conditions and worst-case scenarios.
  • Assess Toxicological Data: Utilize available toxicological databases to comprehend the health effects of potential leachables.

This proactive approach will set a solid foundation for subsequent testing and is essential for compliance with EMA guidelines.

Step 2: Establishing Analytical Evaluation Threshold (AET) and Dose-Based Threshold (DBT)

In line with risk assessment outcomes, it is critical to establish acceptable thresholds for identified E&L. The analytical evaluation threshold (AET) establishes a guideline for the minimum concentration of leachables that need to be quantified and characterized. Conversely, the dose-based threshold (DBT) calculates the threshold concentration based on the maximum daily dose of the drug.

The following steps explain how to perform calculations for AET and DBT:

Calculating AET

The AET can be calculated based on the following formula:

AET = (0.15 mg/day) / (the maximum daily dose in mg) x (1 or specified number of dosage forms)

Review each component of the equation and ensure your calculations align with thresholds provided in the PQRI guideline.

Calculating DBT

The DBT allows for an understanding of which substances are significant relative to the maximum daily dose:

DBT = (acceptable exposure limit) / (maximum daily dose) x (body weight)

It is crucial that both AET and DBT are documented thoroughly, as these evaluations will play a pivotal role in regulatory submissions and audits.

Step 3: Performing Comprehensive CCI Testing

Container closure integrity (CCI) testing is an essential step in qualifying packaging systems. It assesses whether a container is effectively sealed and can protect the drug product throughout its lifecycle. There are various methods used to test CCI:

  • Visual Inspection: Check for any physical defects such as cracks, seal misalignment, or deformations.
  • Vacuum Decay Testing: A vacuum is achieved within the container; if there is any leak, the vacuum will degrade, indicating a breach.
  • Pressure Decay Testing: Similar to vacuum testing but focuses on positive pressure, detecting leaks accordingly.
  • Dielectric Spectroscopy: Measures changes in material properties when subjected to electrical fields, indicative of breaches in closure.

Utilizing these testing methods in combination can provide a robust assessment of CCI, ensuring that the packaged product remains safe for consumption.

Step 4: Implementing Single-Use Systems Validation

Single-use systems have gained popularity within the pharmaceutical industry due to their flexibility and reduced contamination risks. It is critical to perform validation studies on these systems, particularly when considering E&L and CCI aspects. The validation process should include:

  • Vendor Qualification: Ensuring that the suppliers of single-use systems adhere to cGMP requirements and have robust quality assurance systems.
  • Material Compatibility Testing: Assessing the compatibility of the single-use systems with the drug product to prevent potential leachables.
  • Performance Qualification: Ensuring that systems function as intended during actual manufacturing processes.

Additionally, as per EU GMP Annex 1, special attention must be placed on the validation of single-use systems to prevent contamination and ensure product integrity.

Step 5: Establishing a Regulatory-Compliant Quality Management System (QMS)

Finally, a robust Quality Management System (QMS) is essential for coordinating all validation activities, including E&L and CCI testing. A comprehensively documented QMS ensures that all processes are compliant with global regulations and standards issued by bodies like the WHO, FDA, and EMA.

Key components of the QMS should include:

  • Standard Operating Procedures (SOPs): Establish clear procedures for conducting E&L testing, risk assessments, and CCI evaluations.
  • Training Programs: Ensure that all employees involved in validation activities are adequately trained and maintain proficiency in required techniques.
  • Documentation Practices: Maintain thorough and accurate records of all validation activities to facilitate audits and inspections.

The implementation of a comprehensive QMS will not only streamline validation processes but will also help in addressing any regulatory findings effectively.

Conclusion

The pharmaceutical industry continues to evolve, bringing functional and safety challenges, particularly with emerging technologies and changes in regulatory expectations. Therefore, it is crucial to continuously update and maintain best practices surrounding E&L assessments and CCI testing. By implementing a robust risk management strategy that includes AET and DBT calculations, comprehensive CCI testing, validation of single-use systems, and a rigorous QMS, pharmaceutical professionals can enhance product integrity and ensure compliance with regulatory standards.

Remember, vigilance, documentation, and continuous improvement are key to preventing future CCI findings and ensuring the efficacy and safety of drug products in this ever-regulating landscape.